


CLAIMS

1. A compound of Formula I:



Formula I

5 or a pharmaceutically acceptable salt thereof,
wherein

R¹ represents

H,

C₂-C₆ alkyl substituted with 0, 1 or 2 substituents selected from the group
consisting of OR⁶, SR⁷, NR⁸R⁹, halogen, thiazole, oxazole and pyrazole,
C₃-C₆ cycloalkyl substituted with 0, 1 or 2 substituents selected from the group
consisting of OR⁶, SR⁷ and NR⁸R⁹,

thiazole,

benzyl wherein the phenyl moiety is substituted with 0, 1 or 2 substituents
selected from the group consisting of OR⁶, SR⁷ and NR⁸R⁹, or
(CH₂)_m-R¹⁰,

R² represents

H,

F,

Cl,

C₂-C₆ alkyl substituted with 0, 1 or 2 substituents selected from the group
consisting of OR⁶, SR⁷, NR⁸R⁹, halogen, thiazole, oxazole and pyrazole,
C₃-C₆ cycloalkyl substituted with 0, 1 or 2 substituents selected from the group
consisting of OR⁶, SR⁷ and NR⁸R⁹,


benzyl wherein the phenyl moiety is substituted with 0, 1 or 2 substituents
selected from the group consisting of OR⁶, SR⁷ and NR⁸R⁹, or

$(\text{CH}_2)_m\text{-R}^{10}$,


provided that R^1 and R^2 are not both H,

- 5 R^3 represents
 H,
 halogen, or
 $\text{C}_1\text{-C}_3$ alkyl substituted with 0, 1, 2 or 3 halogens selected from the group
 consisting of F and Cl,
- 10 R^4 and R^5 independently represent $\text{C}_1\text{-C}_6$ alkyl substituted with 0, 1, 2 or 3 F,
- X represents CH=CH, CH, N, NH, O or S;
 Y represents CH=CH, CH, N, NH, O or S,
- 15 provided that:
 (a) X and Y are not the same,
 (b) when X represents CH=CH then Y may only represent CH, and
 (c) when Y represents CH=CH then X may only represent CH,
 Z represents a single bond, O or S,
- 20 R^6 , R^7 , R^8 and R^9 independently represent
 H, or
 $\text{C}_1\text{-C}_3$ alkyl substituted with 0,1, 2 or 3 F,
- R^{10} is selected from the group consisting of phenyl, thiazole, oxazole and
25 pyrazole,
 n is 0, 1, 2, 3 or 4, and
 m is 0 or 1.
2. A compound as claimed in Claim 1, or a pharmaceutically acceptable salt thereof,
30 which is a compound of Formula Ia, Formula Ib, Formula Ic or Formula Id:


113




Formula Ia,



Formula Ib,



Formula Ic,



Formula Id.

- 5
3. A compound as claimed any one of the preceding claims, wherein R¹ represents C₂-C₆ alkyl substituted with 0, 1 or 2 substituents selected from the group consisting of OR⁶, SR⁷, NR⁸R⁹, halogen, thiazole, oxazole and pyrazole.
 - 10 4. A compound as claimed in any one of the preceding claims, wherein R² and R³ independently represent H.
 5. A compound as claimed in Claims 3 and 4, wherein R¹ is *tert*-butyl, isopropyl or cyclopropyl.
 - 15 6. A compound as claimed in Claims 3 and 4, wherein R¹ is C₂-C₆ alkyl substituted by an -OH group or a F atom.

7. A compound as claimed in Claim 6, wherein R¹ is 2-hydroxyprop-2-yl, 1-ethanol or 2-fluoroprop-2-yl.
- 5 8. A compound as claimed in any one of the preceding claims, wherein R⁴ is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl, and *tert*-butyl.
9. A compound as claimed in Claim 8, wherein R⁴ is methyl or *n*-butyl.
- 10 10. A compound as claimed in any one of the preceding claims, wherein R⁵ is selected from the group consisting of ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *sec*-butyl and *tert*-butyl.
- 15 11. A compound as claimed in Claim 10, wherein R⁵ is isopropyl or isobutyl.
12. A compound as claimed in any one of the preceding claims, wherein n is 0.
13. A compound as claimed in any one of the preceding claims, wherein Z is a single
20 bond.
14. A compound as claimed in any one of the preceding claims, which is one or more of the following:
methyl ((4'-((2-(*tert*-butyl)-1*H*-imidazol-1-yl)methyl)-5-isobutyl-[1,1'-
25 biphenyl]-2-yl)sulfonyl)carbamate,
butyl ((4'-((2-(*tert*-butyl)-1*H*-imidazol-1-yl)methyl)-5-isobutyl-[1,1'-biphenyl]-
2-yl)sulfonyl)carbamate,
methyl ((4-(4-((2-(*tert*-butyl)-1*H*-imidazol-1-yl)methyl)phenyl)-2-
isobutylthiazol-5-yl)sulfonyl) carbamate,
30 butyl ((4-(4-((2-(*tert*-butyl)-1*H*-imidazol-1-yl)methyl)phenyl)-2-
isobutylthiazol-5-yl)sulfonyl) carbamate,
methyl ((4-(4-((2-(*tert*-butyl)-1*H*-imidazol-1-yl)methyl)phenyl)-2-
propylthiazol-5-yl)sulfonyl)carbamate,
butyl ((4-(4-((2-(*tert*-butyl)-1*H*-imidazol-1-yl)methyl)phenyl)-2-propylthiazol-
35 5-yl)sulfonyl) carbamate,
butyl ((4'-((2-(2-hydroxypropan-2-yl)-1*H*-imidazol-1-yl)methyl)-5-isobutyl-
[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,

- methyl ((4'-((2-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)methyl)-5-isobutyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
butyl ((4'-((2-(*tert*-butyl)-1H-imidazol-1-yl)methyl)-5-propyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
5 methyl ((4'-((2-(*tert*-butyl)-1H-imidazol-1-yl)methyl)-5-propyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
butyl ((3-(4-((2-(*tert*-butyl)-1H-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate,
methyl ((3-(4-((2-(*tert*-butyl)-1H-imidazol-1-yl)methyl)phenyl)-5-isobutylthiophen-2-yl)sulfonyl)carbamate,
10 butyl ((4-(4-((2-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-propylthiazol-5-yl)sulfonyl)carbamate,
butyl ((4-(4-((2-isopropyl-1H-imidazol-1-yl)methyl)phenyl)-2-propylthiazol-5-yl)sulfonyl)carbamate,
15 butyl ((2-isobutyl-4-(4-((2-(thiazol-2-yl)-1H-imidazol-1-yl)methyl)phenyl)thiazol-5-yl)sulfonyl)carbamate,
butyl ((4-(4-((2-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-isobutylthiazol-5-yl)sulfonyl)carbamate,
butyl ((2-isobutyl-4-(4-((2-isopropyl-1H-imidazol-1-yl)methyl)phenyl)thiazol-5-yl)sulfonyl)carbamate,
20 methyl ((4-(4-((2-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-isobutylthiazol-5-yl)sulfonyl)carbamate,
methyl ((2-isobutyl-4-(4-((2-isopropyl-1H-imidazol-1-yl)methyl)phenyl)thiazol-5-yl)sulfonyl)carbamate,
25 butyl ((2-propyl-4-(4-((2-(thiazol-2-yl)-1H-imidazol-1-yl)methyl)phenyl)thiazol-5-yl)sulfonyl)carbamate,
butyl ((4-(4-((2-(1-hydroxyethyl)-1H-imidazol-1-yl)methyl)phenyl)-2-isobutylthiazol-5-yl)sulfonyl)carbamate,
methyl ((4-(4-((2-(1-hydroxyethyl)-1H-imidazol-1-yl)methyl)phenyl)-2-isobutylthiazol-5-yl)sulfonyl)carbamate,
30 butyl ((4-(4-((2-(1-hydroxyethyl)-1H-imidazol-1-yl)methyl)phenyl)-2-propylthiazol-5-yl)sulfonyl)carbamate,
methyl ((4-(4-((2-(1-hydroxyethyl)-1H-imidazol-1-yl)methyl)phenyl)-2-propylthiazol-5-yl)sulfonyl)carbamate,
35 methyl ((4-(4-((2-(cyclopropyl-1H-imidazol-1-yl)methyl)phenyl)-2-isobutylthiazol-5-yl)sulfonyl)carbamate,

- butyl ((4-(4-((2-cyclopropyl-1H-imidazol-1-yl)methyl)phenyl)-2-isobutylthiazol-5-yl)sulfonyl)carbamate,
methyl ((4-(4-((2-cyclopropyl-1H-imidazol-1-yl)methyl)phenyl)-2-propylthiazol-5-yl)sulfonyl)carbamate,
5 butyl ((4-(4-((2-cyclopropyl-1H-imidazol-1-yl)methyl)phenyl)-2-propylthiazol-5-yl)sulfonyl)carbamate,
methyl ((4'-((2-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)methyl)-5-propyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
10 butyl ((4'-((2-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)methyl)-5-propyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
butyl ((4'-((2-(2-fluoropropan-2-yl)-1H-imidazol-1-yl)methyl)-5-isobutyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
methyl ((5-isobutyl-4'-((2-(thiazol-2-yl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
15 methyl ((4'-((2-(2-fluoropropan-2-yl)-1H-imidazol-1-yl)methyl)-5-isobutyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
butyl ((5-isobutyl-4'-((2-(thiazol-2-yl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
methyl ((5-isobutyl-4'-((2-(isopropan-2-yl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
20 butyl ((5-isobutyl-4'-((2-(isopropan-2-yl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
butyl ((5-isobutyl-4'-((2-(cyclopropan-2-yl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
25 methyl ((5-isobutyl-4'-((2-(cyclopropan-2-yl)-1H-imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate,
butyl ((5-isobutyl-3-(4-(2-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-yl)sulfonyl)carbamate,
methyl ((5-isobutyl-3-(4-(2-(2-hydroxypropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-yl)sulfonyl)carbamate,
30 butyl ((5-isobutyl-3-(4-(2-(2-fluoropropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-yl)sulfonyl)carbamate,
methyl ((5-isobutyl-3-(4-(2-(2-fluoropropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-yl)sulfonyl)carbamate,
35 2-methoxyethyl ((5-isobutyl-3-(4-(2-(2-tertbutyl)-1H-imidazol-1-yl)methyl)phenyl)-2-yl)sulfonyl)carbamate,

- butyl ((4-(4-((2-(2-fluoropropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-propyl thiazol-5-yl)sulfonyl)carbamate,
 methyl ((4-(4-((2-(2-fluoropropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-propyl thiazol-5-yl)sulfonyl)carbamate,
 5 butyl ((4-(4-((2-(2-fluoropropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-isobutylthiazol-5-yl)sulfonyl)carbamate,
 methyl ((4-(4-((2-(2-fluoropropan-2-yl)-1H-imidazol-1-yl)methyl)phenyl)-2-isobutylthiazol-5-yl)sulfonyl)carbamate,
 butyl ((4'-((2-(tert-butyl)-1H-imidazol-1-yl)methyl)-3'-fluoro-5-isobutyl-[1,1'-
 10 biphenyl]-2-yl)sulfonyl)carbamate, or
 methyl ((4'-((2-(tert-butyl)-1H-imidazol-1-yl)methyl)-3'-fluoro-5-isobutyl-[1,1'-biphenyl]-2-yl)sulfonyl)carbamate.
- 15 15. A compound as defined in any one of Claims 1 to 14, for use as a medicament.
16. A pharmaceutical composition comprising a therapeutically effective amount of a compound as claimed in any one of Claims 1 to 14, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.
- 20 17. A compound as defined in any one of the preceding claims, for treating and/or preventing a disease, disorder or condition associated with angiotensin II wherein said compound exhibits an acceptable level of CYP inhibition of one or more CYPs.
- 25 18. A compound as defined in Claim 17, for use in the treatment and/or prevention of a disease, disorder and/or condition selected from the group consisting of hypertension, heart failure, stroke, chronic kidney disease, nephropathy, pulmonary fibrosis such as idiopathic pulmonary fibrosis, sclerosis such as systemic sclerosis, sarcoidosis such as pulmonary sarcoidosis, obstructive lung
 30 diseases, such as chronic obstructive lung disease, autoimmune diseases, such as rheumatoid arthritis, viral respiratory tract infections and pneumonia as a consequence thereof, and any combination thereof.
19. The use of a compound as defined in Claim 17, for the manufacture of a
 35 medicament for the treatment of a disease, disorder and/or condition selected from the group consisting of hypertension, heart failure, stroke, chronic kidney disease, nephropathy, pulmonary fibrosis such as idiopathic pulmonary fibrosis,


sclerosis such as systemic sclerosis, sarcoidosis such as pulmonary sarcoidosis, obstructive lung diseases, such as chronic obstructive lung disease, autoimmune diseases, such as rheumatoid arthritis, viral respiratory tract infections and pneumonia as a consequence thereof, and any combination thereof.

- 5
20. A method of treatment of disease, disorder and/or condition selected from the group consisting of hypertension, heart failure, stroke, chronic kidney disease, nephropathy, pulmonary fibrosis such as idiopathic pulmonary fibrosis, sclerosis such as systemic sclerosis, sarcoidosis such as pulmonary sarcoidosis, 10 obstructive lung diseases, such as chronic obstructive lung disease, autoimmune diseases, such as rheumatoid arthritis, viral respiratory tract infections and pneumonia as a consequence thereof, which comprises administering a compound as defined in any one of Claims 1 to 14 to a patient in need of such treatment.
- 15
21. A compound for use as claimed in Claim 18, a use as claimed in Claim 19, or a method of treatment as claimed in Claim 20, wherein the disease is an interstitial lung disease.
- 20
22. A compound for use, a use, or a method of treatment as claimed in Claim 21, wherein the interstitial lung disease is idiopathic pulmonary fibrosis or sarcoidosis.
- 25
23. A compound for use as claimed in Claim 18, a use as claimed in Claim 19, or a method of treatment as claimed in Claim 20, wherein the diseases are heart failure, chronic kidney disease, rheumatoid arthritis and virally-induced pneumonia.
- 30
24. A pharmaceutical formulation comprising a compound as defined in any one of Claims 1 to 14, a therapeutic agent that is known to be metabolized by a CYP enzyme; and a pharmaceutically-acceptable adjuvant, diluent or carrier.
- 35
25. A kit of parts comprising:
(A) A pharmaceutical formulation including a compound as defined in any one of Claims 1 to 14 in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier; and

(B) A pharmaceutical formulation including a therapeutic agent that is known to be metabolized by a CYP enzyme, in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier,
 which components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.


26. A formulation as claimed in Claim 24, or a kit of parts as claimed in Claim 25, wherein the therapeutic agent is selected from the group consisting of pirfenidone, naproxen, propranolol, riluzole, tizanidine, warfarin, celecoxib, clopidogrel, irbesartan, meloxicam, piroxicam, tosemede, cyclophosphamide, indomethacin, atorvastatin, cilostazol, cyclosporine, deflazacort, hydrocortisone, lidocaine, selexipag, sildenafil and/or simvastatin.

A process for the preparation of a compound of Formula I as defined in any one of the preceding claims, by reaction of a compound of Formula 5,




Formula 5

wherein R^1 , R^2 , R^3 , R^5 , X, Y, Z and n are as defined in Claim 1 with a compound of Formula 6,



wherein X represents a suitable leaving group, such as halo (e.g. chloro), and R^4 is as defined in Claim 1, optionally following deprotection of a compound of Formula 4,

121



Formula 4

wherein PG represents a protecting group and R¹, R², R³, R⁵, X, Y, Z and n are as defined above to yield a compound of Formula 5 as an intermediate.